Monitor for initial purchase order amounts from Fosun Diagnostics, particularly TB-research related orders in Thailand. Any disclosed order value would provide the first tangible revenue signal for ImmuneSelect.
Price Chart
Executive Summary
Virax Biolabs announced an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect research-use immune profiling product line, covering six Southeast Asian markets. The agreement establishes a framework for purchase-order-driven supply with potential for near-term revenue, though no guaranteed minimums or financial terms were disclosed.
Key Facts
- Exclusive commercial supply agreement with Fosun Diagnostics for ImmuneSelect product line
- Covers Thailand, Vietnam, Indonesia, Philippines, Singapore, and Malaysia
- Immediate supply under purchase orders with volume-based pricing tiers
- Initial focus on tuberculosis-related research applications in Thailand
- Fosun Pharma reported 2025 revenue of approximately US $5.8 billion
- No upfront payment or guaranteed minimum purchase disclosed
Financial Impact
No financial terms disclosed; potential near-term revenue from purchase orders, but magnitude unclear
Risk Factors
- No minimum purchase commitments disclosed; revenue dependent on actual purchase orders
- ImmuneSelect is a research-use-only product line, distinct from ViraxImmune diagnostic platform
- Small market cap company ($3M) with limited operating history and commercial scale
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-299132 |
| Document: vrax-ex99_1.htm | 0001193125-26-299132 |
| Document: 0001193125-26-299132-index-headers.html | 0001193125-26-299132 |
| Document: 0001193125-26-299132-index.html | 0001193125-26-299132 |
| Document: 0001193125-26-299132.txt | 0001193125-26-299132 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 6-K | $1.85 | awaiting T+60 | — | $1.19 (−35.68%) |
Sep 4, 2026 7w ago | 6-K | $2.63 | awaiting T+60 | — | $1.19 (+54.75%) |
Sep 4, 2026 7w ago | EFFECT | $2.63 | awaiting T+60 | — | $1.19 (−54.67%) |
Aug 18, 2026 9w ago | 6-K | $2.76 | awaiting T+60 | — | $1.19 (−56.88%) |
Jul 31, 2026 12w ago | 6-K | $2.62 $1.19 | ▲ +54.58% | ▲ +57.04% | $1.19 (+54.58%) |
Jul 16, 2026 14w ago | 6-K | $3.90 $1.87 | ▼ −52.05% | ▼ −55.76% | $1.19 (−69.49%) |
Jul 9, 2026 15w ago | Press Release | $6.36 $2.20 | ▲ +65.41% | ▲ +67.04% | $1.19 (+81.29%) |
Jul 9, 2026 15w ago | 6-K | $6.36 $2.20 | ▼ −65.41% | ▼ −67.04% | $1.19 (−81.29%) |
Jun 24, 2026 17w ago | 6-K | $0.1350 $0.0924 | ▼ −31.56% | ▼ −36.89% | $1.19 (+781.48%) |
Jun 12, 2026 19w ago | 6-K | $0.1840 $0.1092 | ▼ −40.65% | ▼ −43.44% | $1.19 (+546.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers